Thực trạng sử dụng thuốc sinh học trong điều trị viêm khớp cột sống tại Bệnh viện Đại học Y Hà Nội

Abstract

Biologic therapy has ushered in a new era in the management of ankylosing spondylitis, including both axial and peripheral forms. We conducted a study on 89 ankylosing spondylitis patients (diagnosed according to the ASAS 2009 and 2011 criteria) currently undergoing biologic therapy. The study was conducted to describe current patterns of biologic use in the treatment of ankylosing spondylitis at the Department of Rheumatology, Hanoi Medical University Hospital, from March 2024 to November 2025. Results: TNF-α inhibitors were the most frequently prescribed first-line biologic agents (58.43%), followed by IL-17A inhibition with secukinumab (41.57%). Biologic switching occurred in 21.35% of patients. Secukinumab was the most commonly selected agent after the first switch, accounting for 36.11%. Following the second switch, adalimumab, golimumab, and secukinumab were prescribed at comparable frequencies. The 3-year treatment retention rate for biologic therapy was 77.53%. Dose tapering or spacing was observed in 59.55% of patients, and 22.47% discontinued biologic therapy. The most frequently reported reasons for dose modification, treatment discontinuation, or non-adherence included favorable clinical response and financial considerations.